Verrica Pharmaceuticals Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Verrica Pharmaceuticals Inc. (VRCA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$13.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$13.15M, a 6547.55% decline year-over-year.
- Verrica Pharmaceuticals Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $204.00K.
- Verrica Pharmaceuticals Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-06-30 was -$17.19M.
- Verrica Pharmaceuticals Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$24.80M, a 29981.93% decline year-over-year.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|---|
| 2026-06-30 | -$13.15M 10-Q · filed 2026-08-06 | -$22.84M 10-Q · filed 2026-08-06 | |
| 2025-06-30 | $204.00K 10-Q · filed 2026-08-06 | -$9.54M 10-Q · filed 2026-08-06 | |
| 2024-06-30 | -$17.19M 10-Q · filed 2025-08-12 | -$37.52M 10-Q · filed 2025-08-12 | |
| 2023-09-30 | -$24.80M 10-Q · filed 2023-11-09 | -$42.38M 10-Q · filed 2023-11-09 | |
| 2022-09-30 | $83.00K 10-Q · filed 2023-11-09 | -$18.55M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |